Michael Ulz
Stock Analyst at Morgan Stanley
(3.71)
# 662
Out of 4,829 analysts
119
Total ratings
45%
Success rate
9.18%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Ulz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLN Silence Therapeutics | Maintains: Overweight | $45 → $25 | $3.83 | +552.74% | 12 | May 9, 2025 | |
| VKTX Viking Therapeutics | Maintains: Overweight | $105 → $102 | $28.30 | +260.42% | 3 | Apr 24, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $284 → $268 | $270.19 | -0.81% | 10 | Apr 11, 2025 | |
| KYTX Kyverna Therapeutics | Maintains: Overweight | $40 → $20 | $2.21 | +804.98% | 2 | Apr 1, 2025 | |
| CABA Cabaletta Bio | Maintains: Overweight | $30 → $22 | $1.29 | +1,605.43% | 6 | Apr 1, 2025 | |
| AARD Aardvark Therapeutics | Initiates: Overweight | $29 | $10.97 | +164.36% | 1 | Mar 10, 2025 | |
| YMAB Y-mAbs Therapeutics | Maintains: Underweight | $11 → $7 | $4.07 | +71.99% | 7 | Mar 5, 2025 | |
| KPTI Karyopharm Therapeutics | Maintains: Outperform | $75 → $54 | $6.15 | +778.05% | 5 | Mar 3, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $24 → $20 | $1.93 | +936.27% | 4 | Feb 28, 2025 | |
| THRD Third Harmonic Bio | Downgrades: Equal-Weight | $20 → $5 | $5.17 | -3.29% | 5 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $10 | $1.71 | +484.80% | 2 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $46 → $96 | $41.53 | +131.16% | 4 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $52 | $12.56 | +314.01% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $110 → $115 | $100.27 | +14.69% | 9 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $57 | $45.57 | +25.08% | 3 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $36 → $27 | $13.97 | +93.27% | 4 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $7 | $1.07 | +554.21% | 8 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $45 → $48 | $33.53 | +43.16% | 4 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $27 | $5.41 | +399.08% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $30 → $20 | $3.26 | +513.50% | 3 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $7.00 | +542.86% | 1 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $10 | $0.73 | +1,267.99% | 3 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $6 → $8 | $0.33 | +2,327.18% | 5 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $3 | $2.32 | +29.31% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $18 → $30 | $5.30 | +466.04% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $25 → $30 | $1.19 | +2,421.01% | 3 | Mar 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $6.92 | +550.29% | 1 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $20 | $0.36 | +5,446.31% | 2 | May 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $80 | $36.09 | +121.67% | 3 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $15 | $6.22 | +141.35% | 3 | Jul 12, 2017 |
Silence Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $45 → $25
Current: $3.83
Upside: +552.74%
Viking Therapeutics
Apr 24, 2025
Maintains: Overweight
Price Target: $105 → $102
Current: $28.30
Upside: +260.42%
Alnylam Pharmaceuticals
Apr 11, 2025
Maintains: Equal-Weight
Price Target: $284 → $268
Current: $270.19
Upside: -0.81%
Kyverna Therapeutics
Apr 1, 2025
Maintains: Overweight
Price Target: $40 → $20
Current: $2.21
Upside: +804.98%
Cabaletta Bio
Apr 1, 2025
Maintains: Overweight
Price Target: $30 → $22
Current: $1.29
Upside: +1,605.43%
Aardvark Therapeutics
Mar 10, 2025
Initiates: Overweight
Price Target: $29
Current: $10.97
Upside: +164.36%
Y-mAbs Therapeutics
Mar 5, 2025
Maintains: Underweight
Price Target: $11 → $7
Current: $4.07
Upside: +71.99%
Karyopharm Therapeutics
Mar 3, 2025
Maintains: Outperform
Price Target: $75 → $54
Current: $6.15
Upside: +778.05%
Iovance Biotherapeutics
Feb 28, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $1.93
Upside: +936.27%
Third Harmonic Bio
Feb 12, 2025
Downgrades: Equal-Weight
Price Target: $20 → $5
Current: $5.17
Upside: -3.29%
Feb 3, 2025
Maintains: Overweight
Price Target: $18 → $10
Current: $1.71
Upside: +484.80%
Jan 28, 2025
Maintains: Overweight
Price Target: $46 → $96
Current: $41.53
Upside: +131.16%
Aug 14, 2024
Maintains: Overweight
Price Target: $48 → $52
Current: $12.56
Upside: +314.01%
Jul 12, 2024
Maintains: Equal-Weight
Price Target: $110 → $115
Current: $100.27
Upside: +14.69%
Jun 18, 2024
Maintains: Overweight
Price Target: $53 → $57
Current: $45.57
Upside: +25.08%
May 13, 2024
Maintains: Equal-Weight
Price Target: $36 → $27
Current: $13.97
Upside: +93.27%
Feb 27, 2024
Maintains: Equal-Weight
Price Target: $3 → $7
Current: $1.07
Upside: +554.21%
Nov 3, 2023
Maintains: Equal-Weight
Price Target: $45 → $48
Current: $33.53
Upside: +43.16%
Aug 16, 2023
Maintains: Outperform
Price Target: $15 → $27
Current: $5.41
Upside: +399.08%
Mar 24, 2023
Maintains: Equal-Weight
Price Target: $30 → $20
Current: $3.26
Upside: +513.50%
Feb 1, 2023
Initiates: Overweight
Price Target: $45
Current: $7.00
Upside: +542.86%
Jan 27, 2023
Maintains: Overweight
Price Target: $20 → $10
Current: $0.73
Upside: +1,267.99%
Jan 27, 2023
Maintains: Equal-Weight
Price Target: $6 → $8
Current: $0.33
Upside: +2,327.18%
Jan 27, 2023
Downgrades: Equal-Weight
Price Target: $3
Current: $2.32
Upside: +29.31%
Jan 27, 2023
Upgrades: Equal-Weight
Price Target: $18 → $30
Current: $5.30
Upside: +466.04%
Mar 30, 2022
Maintains: Equal-Weight
Price Target: $25 → $30
Current: $1.19
Upside: +2,421.01%
Oct 8, 2020
Initiates: Outperform
Price Target: $45
Current: $6.92
Upside: +550.29%
May 28, 2020
Maintains: Outperform
Price Target: $12 → $20
Current: $0.36
Upside: +5,446.31%
Nov 3, 2017
Maintains: Outperform
Price Target: $85 → $80
Current: $36.09
Upside: +121.67%
Jul 12, 2017
Maintains: Outperform
Price Target: $12 → $15
Current: $6.22
Upside: +141.35%